|
 In 2011, the British-based group was one of the first multinational
companies to announce plans to step up medicine production in Russia
following moves by Moscow to support local industry by imposing
tougher rules on imported drugs.
It is the largest foreign investment in the construction of a new
pharmaceutical facility in the country.
The company said the plant in the Kaluga region southwest of Moscow
would reach full capacity in 2017 and would produce about 40 million
packs and 850 million tablets of some 30 medicines every year.
This represents more than 60 percent of the medicines sold in Russia
by AstraZeneca.
Soriot has made emerging markets a priority area for growth and
Russia is an important market within that, with the company's sales
there increasing 30 percent to $116 million in the first half of
2015.
[to top of second column] |
Other pharmaceutical firms including Novartis, Sanofi, Novo Nordisk
and Pfizer have also pledged increased investment in production and
research in Russia in recent years to help ensure market access.
(Reporting by Ben Hirschler; editing by David Clarke)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
